Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis

Cody Paiva, J. Claire Godbersen, Taylor Rowland, Olga V. Danilova, Christopher Danes, Allison Berger, Alexey V. Danilov

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

While death receptor ligands (Fas and TRAIL) kill chemoresistant tumor cell lines, related therapies have limited clinical efficacy as single agents. Death receptor signaling is modulated by nuclear factor-κB (NFκB), a family of transcription factors which are constitutively active in B-cell malignancies. We and others have shown that pevonedistat, an investigational inhibitor of the NEDD8-activating enzyme, abrogates NFκB activity in B-cell neoplasia. Here we demonstrate that diffuse large B-cell lymphoma, particularly activated B-cell type, and primary chronic lymphocytic leukemia cells are re-sensitized to extrinsic apoptosis by pevonedistat. Pevonedistat enhanced caspase-8 processing following death receptor ligation, and downmodulated cFLIP, a NFκB-regulated protease-deficient caspase homolog. However, treatment with pevonedistat did not modulate death-inducing signaling complex in neoplastic B-cells, suggesting that they were sensitized to death ligands through the mitochondrial pathway. Our data provide rationale for further development of pharmacologic agents including pevonedistat in strategies which enhance death receptor signaling in lymphoid malignancies.

Original languageEnglish (US)
Pages (from-to)21128-21139
Number of pages12
JournalOncotarget
Volume8
Issue number13
DOIs
StatePublished - 2017

Keywords

  • CLL
  • Lymphoma
  • Neddylation
  • TRAIL

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis'. Together they form a unique fingerprint.

  • Cite this